{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:39:31Z","timestamp":1791207571799,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010816","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,4,20]],"date-time":"2016-04-20T00:00:00Z","timestamp":1461110400000}}],"reference-count":81,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010816.pub2","type":"journal-article","created":{"date-parts":[[2016,4,20]],"date-time":"2016-04-20T15:27:51Z","timestamp":1461166071000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Bortezomib for the treatment of multiple myeloma"],"prefix":"10.1002","volume":"2016","author":[{"given":"Kathleen","family":"Scott","sequence":"first","affiliation":[{"name":"Trinity College Dublin; School of Nursing & Midwifery; 24 D'Olier St Dublin Ireland"},{"name":"All Ireland Cooperative Oncology Research Group (ICORG); 60 Fitzwilliam Square Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J","family":"Hayden","sequence":"additional","affiliation":[{"name":"St James\u00b4s Hospital; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Will","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50937"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Wheatley","sequence":"additional","affiliation":[{"name":"University of Birmingham; Cancer Research Clinical Trials Unit, School of Cancer Sciences; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imelda","family":"Coyne","sequence":"additional","affiliation":[{"name":"Trinity College Dublin; School of Nursing & Midwifery; 24 D'Olier St Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,20]]},"reference":[{"key":"10.1002\/14651858.CD010816.pub2-BIB0001|cit1","unstructured":"Sahai S Kumar L Raina V Sharma A Gupta R Mahajan S Multiple myeloma with light chain-induced acute renal failure - role of bortezomib-dexamethasone & cyclophosphamide-thalidomide & dexamethasone: a prospective randomized study (Abstract 3648) Proceedings of the European Cancer Congress Amsterdam"},{"issue":"29","key":"10.1002\/14651858.CD010816.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010816.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2008.07378.x","article-title":"Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study","volume":"143","author":"Lee","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"24","key":"10.1002\/14651858.CD010816.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD010816.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD010816.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD010816.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2008.07359.x","article-title":"Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma","volume":"143","author":"Jagannath","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"8","key":"10.1002\/14651858.CD010816.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosinol","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Rosinol L Oriol A Teruel AL Hernandez D Lopez-Jimenez J De La Rubia J Maintenance therapy after stem-cell transplantation for multiple myeloma with bortezomib\/thalidomide vs.thalidomide vs. alfa2b-interferon: final results of a phase iii pethema\/gem randomized trial Blood (ASH Annual Meeting Abstracts) Abstract 334 2012","DOI":"10.1182\/blood.V120.21.334.334"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Mateos MV Martinez-Lopez J Hernandez MT Martinez R Rosinnol L Ocio EM Comparison of sequential vs alternating administration of bortezomib, melphalan and prednisone (VMP) and lenalidomide plus dexamethasone (Rd) in elderly patients with newly diagnosed multiple myeloma (MM) patients: GEM2010MAS65 trial Blood (ASH Annual Meeting Abstracts) Abstract 178 2014","DOI":"10.1182\/blood.V124.21.178.178"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Mateos MV Martinez-Lopez J Hernandez MT Martinez R Rosinnol L Ocio EM Comparison of sequential vs alternating administration of bortezomib, melphalan and prednisone (VMP) and lenalidomide plus dexamethasone (Rd) in elderly patients with newly diagnosed multiple myeloma (MM) patients: GEM2010MAS65 trial Blood (ASH Annual Meeting Abstracts) Abstract 403 2013","DOI":"10.1182\/blood.V122.21.403.403"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0012|cit12","first-page":"S106","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by continuous bortezomib thalidomide (VMPT-VT) improved survival","volume":"13","author":"Palumbo","year":"2013","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"issue":"7","key":"10.1002\/14651858.CD010816.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"34","key":"10.1002\/14651858.CD010816.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Cavo M Galli M Pantani L Di Raimondo F Crippa C Offidani M Bortezomib-thalidomide-dexamethasone incorporated into autotransplantation is associated with more favorable outcomes after relapse in comparison with thalidomide-dexamethasone plus autotransplantation in multiple myeloma Blood (ASH Annual Meeting Abstracts) Abstract 4210 2012","DOI":"10.1182\/blood.V120.21.4210.4210"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Cavo M Galli M Pezzi A Di Raimondo F Crippa C Offidani M Persistent improvement in clinical outcomes with bortezomib-thalidomide-dexamethasone vs thalidomide-dexamethasone incorporated into double autologous transplantation for multiple myeloma: an updated analysis of phase 3 Gimema-MMY-3006 study Blood (ASH Annual Meeting Abstracts) Abstract 2090 2013","DOI":"10.1182\/blood.V122.21.2090.2090"},{"issue":"1","key":"10.1002\/14651858.CD010816.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"issue":"9758","key":"10.1002\/14651858.CD010816.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Sonneveld P Scheid C van der Holt B el Jarari L Bertsch U Salwender H Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma: extended follow-up of the HOVON-65\/GMMG-HD4 trial Blood (ASH Annual Meeting Abstracts) Abstract 404 2013","DOI":"10.1182\/blood.V122.21.404.404"},{"issue":"24","key":"10.1002\/14651858.CD010816.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"30","key":"10.1002\/14651858.CD010816.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD010816.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD010816.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1002\/cncr.26517","article-title":"A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid","volume":"118","author":"Sharma","year":"2012","journal-title":"Cancer"},{"issue":"20","key":"10.1002\/14651858.CD010816.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","article-title":"Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR\/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"30","author":"Garderet","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD010816.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf","year":"2012","journal-title":"Haematologica"},{"issue":"5","key":"10.1002\/14651858.CD010816.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncology"},{"issue":"23","key":"10.1002\/14651858.CD010816.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","article-title":"Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial","volume":"121","author":"Mellqvist","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD010816.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1600-0609.2012.01775.x","article-title":"Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study","volume":"88","author":"Hjorth","year":"2012","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD010816.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2012.01788.x","article-title":"Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial","volume":"89","author":"Delforge","year":"2012","journal-title":"European Journal of Haematology"},{"issue":"13","key":"10.1002\/14651858.CD010816.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD010816.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010816.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD010816.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2217\/imt.11.104","article-title":"An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation","volume":"3","author":"Spicka","year":"2011","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1002\/14651858.CD010816.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1177\/147323001103900544","article-title":"Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients","volume":"39","author":"Chen","year":"2011","journal-title":"Journal of International Medical Research"},{"issue":"115","key":"10.1002\/14651858.CD010816.pub2-BIB0035|cit35","first-page":"Abstract 285","article-title":"GMMG MM5 trial in newly diagnosed multiple myeloma to evaluate PAD vs VCD induction prior to HDT followed by lenalidomide consolidation and maintenance - first interim analysis on induction","volume":"97","author":"Goldschmidt","year":"2012","journal-title":"Haematologica"},{"issue":"19","key":"10.1002\/14651858.CD010816.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD010816.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Niesvizky R Flinn IW Rifkin RM Gabrail NY Charu V Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients American Society of Hematology 2010","DOI":"10.1182\/blood.V116.21.619.619"},{"issue":"25","key":"10.1002\/14651858.CD010816.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0040|cit40","unstructured":"CLARION Study Ongoing study 2013"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0041|cit41","unstructured":"CR006127 Study Ongoing study 2006"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0042|cit42","unstructured":"CR006124 Study Ongoing study 2006"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0043|cit43","unstructured":"ECOG E1A11 Study Ongoing study 2013"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0044|cit44","unstructured":"ENDEAVOR Study Ongoing study 2012"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0045|cit45","unstructured":"PRO# 1307 Study Ongoing study 2010"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"HOVON 95 Study Ongoing study 2011","DOI":"10.1016\/j.yonc.2011.07.024"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0047|cit47","unstructured":"2081-113 Study Ongoing study 2009"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0048|cit48","unstructured":"CR018796 Study Ongoing study 2013"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0049|cit49","unstructured":"Subcutaneous bortezomib maintenance Study Ongoing study 2013"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0050|cit50","unstructured":"SWOG-S0777 Study Ongoing study 2008"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0051|cit51","unstructured":"CR018751 Study Ongoing study 2012"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0052|cit52","unstructured":"DSMM XIV Study Ongoing study 2012"},{"issue":"3","key":"10.1002\/14651858.CD010816.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1188\/08.CJON.S1.9-12","article-title":"Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board","volume":"12","author":"Bertolotti","year":"2008","journal-title":"Clinical Journal of Oncology Nursing"},{"issue":"3","key":"10.1002\/14651858.CD010816.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Current Cancer Drug Targets"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0055|cit55","article-title":"Chapter 9: Analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","volume":"5.1.0","author":"Deeks","year":"2011"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0056|cit56","unstructured":"Thomson Reuters EndNote 2012"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0058|cit58","article-title":"Chapter 16: Special topics in statistics","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","volume":"5.1.0","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0059|cit59","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","volume":"5.1.0","author":"Higgins","year":"2011"},{"issue":"1","key":"10.1002\/14651858.CD010816.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11899-012-0141-2","article-title":"New proteasome inhibitors in myeloma","volume":"7","author":"Lawasut","year":"2012","journal-title":"Current Haematologic Malignancy Reports"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0062|cit62","article-title":"Chapter 6: Searching for Studies","volume-title":"Cochrane Handbook for Systematic Review of Interventions","volume":"5.1.0","author":"Lefebvre","year":"2011"},{"issue":"7","key":"10.1002\/14651858.CD010816.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"The PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010816.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1002\/14651858.CD010816.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1002\/cncr.28325","article-title":"Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials","volume":"119","author":"Nooka","year":"2013","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"41","key":"10.1002\/14651858.CD010816.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15410","article-title":"The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation","volume":"15","author":"Picot","year":"2011","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","article-title":"Improvement in survival of older adults with multiple myeloma: results of an updated period of analysis of SEER data","volume":"16","author":"Pulte","year":"2011","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0071|cit71","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD010816.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD010816.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0075|cit75","article-title":"Chapter 11: Presenting results and 'Summary of findings' tables","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2011"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/leu.2009.173","article-title":"Proteasome inhibitors in the treatment of multiple myeloma","volume":"23","author":"Shah","year":"2009","journal-title":"Leukemia"},{"issue":"14","key":"10.1002\/14651858.CD010816.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"issue":"26","key":"10.1002\/14651858.CD010816.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials","volume":"31","author":"Sonneveld","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0079|cit79","article-title":"Chapter 10: Addressing reporting biases","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","volume":"5.1.0","author":"Sterne","year":"2011"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD010816.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00277-013-1711-7","article-title":"Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"92","author":"Zeng","year":"2013","journal-title":"Annals of Hematology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010816.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T21:44:29Z","timestamp":1718487869000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010816.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,4,20]]},"references-count":81,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010816.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,20]]}}}